News Related to Sasanlimab

Related coverage linked through entity extraction aliases.

Pfizer Advances Oncology Pipeline with BRAFTOVI Trial Success and HYMPAVZI Expansion

Mar 06, 2026

Pfizer reported positive Phase 3 trial results for BRAFTOVI combination therapy in metastatic colorectal cancer and received FDA Priority Review for HYMPAVZI expansion to hemophilia patients including children.

PD-1 and PD-L1 Inhibitors Market Expands with 200+ Drugs in Development Across 180+ Companies

Feb 19, 2026

A comprehensive market report reveals over 180 companies are developing more than 200 PD-1 and PD-L1 inhibitor drugs, with recent fast-track designations and successful Phase III trial results driving expansion in cancer immunotherapy.